Mathematical Modeling of BCG-based Bladder Cancer Treatment Using Socio-Demographics
Clicks: 108
ID: 281561
2023
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
108 views
25 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #34 of 803 articles by views in arXiv
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 803 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Cancer is one of the most widespread diseases around the world with millions
of new patients each year. Bladder cancer is one of the most prevalent types of
cancer affecting all individuals alike with no obvious prototypical patient.
The current standard treatment for BC follows a routine weekly Bacillus
Calmette-Guerin (BCG) immunotherapy-based therapy protocol which is applied to
all patients alike. The clinical outcomes associated with BCG treatment vary
significantly among patients due to the biological and clinical complexity of
the interaction between the immune system, treatments, and cancer cells. In
this study, we take advantage of the patient's socio-demographics to offer a
personalized mathematical model that describes the clinical dynamics associated
with BCG-based treatment. To this end, we adopt a well-established BCG
treatment model and integrate a machine learning component to temporally adjust
and reconfigure key parameters within the model thus promoting its
personalization. Using real clinical data, we show that our personalized model
favorably compares with the original one in predicting the number of cancer
cells at the end of the treatment, with 14.8% improvement, on average.
| Reference Key |
bunimovich-mendrazitsky2023mathematical
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Elizaveta Savchenko; Ariel Rosenfeld; Svetlana Bunimovich-Mendrazitsky |
| Journal | arXiv |
| Year | 2023 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.